Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new funded collaboration with a large pharmaceutical company to modify the GastroPlus® Advanced Compartmental Absorption and Transit (ACAT™) model in support of ongoing research programs for the treatment of gastrointestinal diseases.

Dr. Viera Lukacova, division chief scientific officer of Simulations Plus, said: “Our GastroPlus ACAT model has, time and again, been independently validated as the most accurate simulation engine for the prediction of oral absorption for drugs and chemicals across species and population groups. This new collaboration will accentuate GastroPlus functionality in local gut delivery through extensions to the mechanisms and physiological databases which underpin the ACAT model. These enhancements will be complemented by improved data handling and workflows to aid our partners in evaluating and developing next-generation treatments for various gastrointestinal diseases. We look forward to leveraging their expertise and the unique data they will be sharing on this important project.”

“Our second announced collaboration in 2022 dovetails perfectly with other active programs to enhance the GastroPlus ACAT model as the preeminent approach for predicting oral product performance, food effect considerations, pH-dependent drug-drug interaction risk, and virtual bioequivalence assessment,” added John DiBella, division president, Simulations Plus. “We are pleased with the confidence and trust our partners have in the GastroPlus platform and with our scientific team, and we look forward to sharing the exciting developments with all users to advance model-informed drug development.”

About Simulations Plus

Serving clients worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | LinkedIn.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220120005392/en/